Maximum tolerated dose of INCB024360 90 days [clinicaltrials_resource:0af653f14678ab582eebd0378e4a2deb]
To determine the maximum tolerated dose (MTD) of INCB024360 when administered with intraperitoneal haploidentical donor NK cells/IL-2 after a nonmyeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum tolerated dose of INCB024360 90 days [clinicaltrials_resource:0af653f14678ab582eebd0378e4a2deb]
To determine the maximum tolerated dose (MTD) of INCB024360 when administered with intraperitoneal haploidentical donor NK cells/IL-2 after a nonmyeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer
Bio2RDF identifier
0af653f14678ab582eebd0378e4a2deb
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0af653f14678ab582eebd0378e4a2deb
measure [clinicaltrials_vocabulary:measure]
Maximum tolerated dose of INCB024360
time frame [clinicaltrials_vocabulary:time-frame]
description
To determine the maximum toler ...... and primary peritoneal cancer
identifier
clinicaltrials_resource:0af653f14678ab582eebd0378e4a2deb
title
Maximum tolerated dose of INCB024360 90 days
@en
type
label
Maximum tolerated dose of INCB ...... 653f14678ab582eebd0378e4a2deb]
@en